(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 December 2011 (08.12.2011)

PCT

(10) International Publication Number
WO 2011/151403 A1

(51) International Patent Classification:
A61K 38/04 (2006.01) *C07K 14/47* (2006.01)
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:
PCT/EP2011/059121

(22) International Filing Date:
1 June 2011 (01.06.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/350,731 2 June 2010 (02.06.2010) US
1009222.9 2 June 2010 (02.06.2010) GB

(71) Applicant *(for all designated States except US)*: **IMMATICS BIOTECHNOLOGIES GMBH** [DE/DE]; Paul-Ehrlich-Strasse 15, 72076 Tuebingen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SINGH, Harpreet** [DE/DE]; Bei den Pferdestaellen 9, 72072 Tuebingen (DE). **WEINSCHENK, Toni** [DE/DE]; Im Morgenrain 15, 73773 Aichwald (DE). **WALTER, Steffen** [DE/DE]; Steinenbergstrasse 2, 72764 Reutlingen (DE).

(74) Agent: **KRAUSS, Jan B.**; Boehmert & Boehmert, Pettenkoferstrasse 20 - 22, 80336 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: IMPROVED CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1

Figure 1

```
  1 MEHQLLCCEV ETIRRAYPDA NLLNDRVLRA MLKAEETCAP SVSYFKCVQK EVLPSMRKIV
                                  CCN-E                       CCN-I

 61 ATWMLEVCEE QKCEEEVFPL AMNYLDRFLS LEPVKKSRLQ LLGATCMFVA SKMKETIPLT
     CCN-A        CCN-004 AND F1 TO F3           CCN-001       CCN-006

121 AEKLCIYTDN SIRPEELLQM ELLLVNKLKW NLAAMTPHDF IEHFLSKMPE AEENKQIIRK
                                  CCN-H                       CCN-J

181 HAQTFVALCA TDVKFISNPP SMVAAGSVVA AVQGLNLRSP NNFLSYYRLT RFLSRVIKCD
                         CCN-003  CCN-B TO D AND G        CCN-002

241 PDCLRACQEQ IEALLESSLR QAQQNMDPKA AEEEEEEEEE VDLACTPTDV RDVDI
                    CCN-007
```

(57) **Abstract**: The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

WO 2011/151403 A1